A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

Trial Profile

A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs TTI 621 (Primary)
  • Indications Mycosis fungoides; Solid tumours
  • Focus Adverse reactions
  • Sponsors Trillium Therapeutics
  • Most Recent Events

    • 25 Jan 2018 Planned number of patients changed from 54 to 240.
    • 11 Aug 2017 According to a Trillium Therapeutics media release, preliminary data expected in the second half of 2017.
    • 22 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top